Last reviewed · How we verify
Levosimendan infusion
Levosimendan infusion is a Calcium sensitizer / inodilator Small molecule drug developed by AHEPA University Hospital. It is currently FDA-approved for Acute decompensated heart failure, Cardiogenic shock.
Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, while also causing vasodilation through opening of ATP-sensitive potassium channels.
Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, while also causing vasodilation through opening of ATP-sensitive potassium channels. Used for Acute decompensated heart failure.
At a glance
| Generic name | Levosimendan infusion |
|---|---|
| Sponsor | AHEPA University Hospital |
| Drug class | Calcium sensitizer / inodilator |
| Target | Cardiac troponin C; ATP-sensitive potassium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Levosimendan binds to cardiac troponin C and enhances the interaction between actin and myosin filaments, thereby increasing myocardial contractility. Simultaneously, it opens ATP-sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing cardiac afterload. This dual mechanism improves cardiac output while reducing myocardial oxygen demand.
Approved indications
- Acute decompensated heart failure
- Cardiogenic shock
Common side effects
- Headache
- Hypotension
- Arrhythmias
- Nausea
Key clinical trials
- Impact Of Using LevosemidanVersus DobutamineOn Right Ventricular Function In AdultPatients Undergoing Elective Valve Replacement Surgery
- Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS (PHASE3)
- Shorter Weaning From Invasive Ventilation With Levosimendan (PHASE4)
- Levosimendan in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal Function
- Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage (PHASE2)
- Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients (PHASE2)
- Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levosimendan infusion CI brief — competitive landscape report
- Levosimendan infusion updates RSS · CI watch RSS
- AHEPA University Hospital portfolio CI
Frequently asked questions about Levosimendan infusion
What is Levosimendan infusion?
How does Levosimendan infusion work?
What is Levosimendan infusion used for?
Who makes Levosimendan infusion?
What drug class is Levosimendan infusion in?
What development phase is Levosimendan infusion in?
What are the side effects of Levosimendan infusion?
What does Levosimendan infusion target?
Related
- Drug class: All Calcium sensitizer / inodilator drugs
- Target: All drugs targeting Cardiac troponin C; ATP-sensitive potassium channels
- Manufacturer: AHEPA University Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute decompensated heart failure
- Indication: Drugs for Cardiogenic shock
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing